Comparison of bone metabolism markers between type 2 diabetes mellitus and non-type 2 diabetes mellitus patients with hip fracture

doi:10.12307/2023.099

Abstract

Abstract: BACKGROUND: Hip fracture and type 2 diabetes mellitus are common and frequently-occurring diseases in older adults and their internal relationship needs further studies.
OBJECTIVE: To compare the levels of bone metabolism markers between type 2 diabetes mellitus and non-type 2 diabetes mellitus patients with hip fracture.
METHODS: Total 743 patients with hip fracture from August 2014 to August 2020 were enrolled in this study. According to the presence or absence of diabetes history, they were further divided into type 2 diabetes mellitus group (T2DM group, n=118) and non-type 2 diabetes mellitus group (non-T2DM group, n=625). Biochemical parameters (fasting blood glucose, alkaline phosphatase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood calcium, and blood phosphorus) and bone metabolism parameters (total serum procollagen type N-terminal propeptide, the age-related type I cross linked C-telopeptide and 25-hydroxyvitamin D) were collected and compared. The correlation between fast blood glucose and triglyceride and bone metabolism parameters was calculated by the Spearman correlation analysis.
RESULTS AND CONCLUSION: The fast blood glucose and triglyceride levels in the T2DM group were significantly higher than those in the non-T2DM group. In addition, the total serum procollagen type N-terminal propeptide (P=0.017) and total serum procollagen type N-terminal propeptide (P=0.007) levels in the T2DM group were significantly lower than those in the non-T2DM group. The correlation coefficients between fasting blood glucose and age-related type I cross linked C-telopeptide, between fasting blood glucose and total serum procollagen type N-terminal propeptide, between triglyceride and total serum procollagen type N-terminal propeptide, and between blood calcium and 25-hydroxyvitamin D were -0.124 (P < 0.001), -0.174 (P < 0.001), 0.075 (P=0.04), and 0.108 (P=0.003), respectively. This cross-sectional study indicated that there is a low bone turnover state (both bone formation and bone resorption) in patients with type 2 diabetes mellitus after hip fractures and the fasting blood glucose levels is negatively correlated with total serum procollagen type N-terminal propeptide and age-related type I cross linked C-telopeptide levels. In addition, good glucose control may be beneficial to bone metabolism and prevent from delayed fracture healing after hip fracture.

Key words: hip fracture, osteoporosis, type 2 diabetes mellitus, bone metabolism marker, fracture healing

CLC Number:

Sun Jiajia, Zhu Haidi, Lu Yun, Zhang Kai. Comparison of bone metabolism markers between type 2 diabetes mellitus and non-type 2 diabetes mellitus patients with hip fracture[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(8): 1156-1160.

Figures/Tables 6

References

[1] OGURTSOVA K, DA ROCHA FERNANDES JD, HUANG Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
[2] Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
[3] Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25:1439-1443.
[4] Nazarzadeh M, Bidel Z, Moghaddam A. Meta-analysis of diabetes mellitus and risk of hip fractures: small-study effect. Osteoporos Int. 2016;27:229-230.
[5] Fan Y, Wei F, Lang Y, et al. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27:219-228.
[6] Schwartz AV. Epidemiology of fractures in type 2 diabetes. Bone. 2016;82:2-8.
[7] Petit MA, Paudel ML, Taylor BC, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010;25:285-291.
[8] Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007;18:427-444.
[9] Tebe C, Martinez-Laguna D, Carbonell-Abella C, et al. The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis. Osteoporos Int. 2019;30:2407-2415.
[10] Mazurenko ES, Malyutina SK, Shcherbakova LV, et al. 2019. [The forearm fractures in patients with diabetes and without diabetes in population sample aged over 50 years (Novosibirsk)]. Probl Endokrinol (Mosk). 2019;65:78-87.
[11] Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem. 2017;63:464-474.
[12] Kanazawa I. Interaction between bone and glucose metabolism [Review]. Endocr J. 2017;64:1043-1053.
[13] Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
[14] Liu XX, Jiang L, Liu Q, et al. Low Bone Turnover Markers in Young and Middle-Aged Male Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2020:6191468.
[15] Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45-49.
[16] Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2016;82:69-78.
[17] BULUT T, DEMIREL F, METIN A. The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2017;30:181-187.
[18] Schwarz PE, Gallein G, Ebermann D, et al. Global Diabetes Survey--an annual report on quality of diabetes care. Diabetes Res Clin Pract. 2013;100:11-18.
[19] Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16:377-390.
[20] Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495-505.
[21] Hsu JY, Cheng CY, Hsu CY. Type 2 diabetes mellitus severity correlates with risk of hip fracture in patients with osteoporosis. Neth J Med. 2018;76:65-71.
[22] Tanner SB. Dual-energy X-ray absorptiometry in clinical practice: new guidelines and concerns. Curr Opin Rheumatol. 2011;23:385-388.
[23] DE LIEFDE II, VAN DER KLIFT M, DE LAET CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16:1713-1720.
[24] Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25:2159-2171.
[25] ELLER-VAINICHER C, CAIROLI E, GRASSI G, et al. Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. J Diabetes Res. 2020;22:7608964.
[26] KARIM L, REZAEE T, VAIDYA R. The effect of type 2 diabetes on bone biomechanics. Curr Osteoporos Rep. 2019;17:291-300.
[27] ASADIPOOYA K, UY EM. Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature. J Endocr Soc. 2019;3:1799-1818.
[28] STARUP-LINDE J, ERIKSEN SA, LYKKEBOE S, et al. Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25:1697-1708.
[29] LEE HS, HWANG JS. Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism. Curr Diab Rep. 2020;20:78.
[30] Holloway-Kew KL, De Abreu LLF, Kotowicz MA, et al. Bone Turnover Markers in Men and Women with Impaired Fasting Glucose and Diabetes. Calcif Tissue Int. 2019;104:599-604.